Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy

Related Clinical Trial
Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy

Official Title

Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP

Brief Summary

      This study will examine the safety and effectiveness of an experimental drug called GDNF
      delivered through an investigational device to treat progressive supranuclear palsy (PSP).
      The drug will be administered directly into the brain through catheters attached to an
      infusion pump implanted in the abdomen. The study will evaluate 1) if the drug is safe and
      well tolerated when given by this method; 2) the performance of the catheters and pump
      system, and 3) the effects of GDNF on PSP symptoms.

      PSP is a rare neurological disease that causes eye movement dysfunction, muscle rigidity,
      slowness of movement, swallowing, speech, emotional, cognitive and personality problems.
      Patients 35 to 75 years old with PSP may be eligible for this study. Candidates will be
      screened at the National Institutes of Health outpatient clinic in Bethesda, MD, with a
      medical history, physical examination, neurological and neuropsychiatric evaluations, blood
      tests, electrocardiogram, CT scan of the brain, and baseline studies including a special eye
      examination, evaluation of symptoms, lumbar puncture (spinal tap) and psychiatric interview.

      Patients enrolled in the study will undergo surgery to place two catheters into the brain and
      two infusion pumps under the skin in the upper abdomen. The surgery will be performed at
      Vanderbilt University Medical Center in Nashville, TN. It will be done under general
      anesthesia and will require a 3 day hospitalization. Within 24 hours after the surgery, a CT
      scan of the brain will be done to ensure the catheters are properly placed. Patients return
      to NIH two weeks after surgery for post-surgery examination and treatment initiation.

      All patients will receive continuous infusions of GNDF through one catheter and placebo (an
      inactive salt solution) through the other for 6 months. Half of the patients will receive
      placebo in the right side of the brain and GNDF in the left, and half will receive GNDF in
      the right side of the brain and placebo in the left. All patients will also undergo the
      following procedures:

      Brief physical examination, and evaluation of symptoms and adverse side effects - every 2
      weeks

      Blood and urine tests - every 2 weeks for the first 2 months and then every 8 weeks until the
      end of the study

      CT scan to check catheter placement - weeks 9 and 27

      Thorough evaluation of symptoms - before beginning treatment and weeks 1, 5, 9, 17 and 27

      Neuropsychiatric evaluation - week 27

      Special eye examination - weeks 1 and 27

      Lumbar puncture - week 27

      Additional blood tests to measure drug concentration and antibodies - 6 times during the
      study

      In addition, some patients may be asked to have positron emission tomography (PET) scans or a
      single photon emission tomography (SPECT) scan, or both.

      The potential benefit of GDNF is unknown. In studies with rats and monkeys, GNDF increased
      the number and size of brain cells containing the chemical messenger dopamine and some
      movement and balance problems were lessened. Earlier studies of GDNF infused into the
      ventricles of patients with Parkinson's disease showed no benefit and no serious harm.
    

Detailed Description

      The safety and initial efficacy of the unilateral intralenticular infusion of
      recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) will be
      compared with the contralateral intralenticular infusion of a placebo solution, both
      continuously administered using chronically implanted catheters and pumps in up to 10
      patients with progressive supranuclear palsy. Safety will be evaluated by analyzing implant-,
      post-implant-, and treatment-emergent adverse events, clinical laboratory test results, and
      disease status. Efficacy will be studied by comparing left and right sided neurologic
      function using validated clinical scales as well as by putative surrogate biochemical and
      radiographic measures.
    

Study Phase

Phase 2

Study Type

Interventional




Condition

Progressive Supranuclear Palsy

Intervention

GDNF & Synchro Med Infusion System


Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

15

Start Date

June 2000

Completion Date

May 2005


Eligibility Criteria

        INCLUSION CRITERIA:

          1. Diagnosis of PSP with bilateral symptoms based on medical history and neurologic
             examination in accordance with NINDS criteria. Those evidencing ratable limb
             dysfunction bilaterally as well as a past history levodopa responsivity will be
             especially sought.

          2. PSP will be considered clinically to be at a moderate to moderately advanced stage
             (PSP Staging System grade BB - DD), associated with ratable parkinsonian signs in the
             limbs bilaterally and a Hoehn and Yahr grade of 3 - 5.

          3. Men or nonpregnant women age 35 to 75 years. Women of childbearing potential must have
             a negative human chorionic gonadotropin (HCG) test result immediately before (within
             48 hours) catheter and pump implantation and repeated again immediately before (within
             48 hours) the start of drug infusion; men and women of childbearing potential must
             practice adequate contraception during the course of the study.

          4. Before any study-specific procedures are performed, the subject and their designated
             representative must give signed informed consent for their participation. All patients
             must sign a Durable Power of Attorney (DPA). Device implantation must occur within 60
             days after a subject consents to participate in the study.

          5. The subject is medically able to undergo the surgical procedures required to implant
             bilateral pumps and intracranial catheters using stereotactic procedures.

        EXCLUSION CRITERIA:

          1. Treatment with levodopa, dopamine agonists or any other antiparkinsonian medications.

          2. Presence of clinically significant psychosis or hallucinations.

          3. Any disorder that precludes a surgical procedure (e.g., bleeding diathesis, signs of
             sepsis or inadequately treated infection) alters wound healing or renders bilateral
             catheter and infusion pump implants unsuitable.

          4. Any history of clinically significant head trauma or cerebrovascular disease or recent
             history (within previous 2 years) of drug or alcohol abuse.

          5. A computed tomography (CT) scan or magnetic resonance image (MRI) of the brain within
             3 months before the implantation procedure that indicates the presence of a central
             nervous system abnormality that may interfere with the assessments of safety or
             biologic effect in this protocol, or represent a surgical risk to the subject.

          6. The presence of an intracranial shunt or catheter system other than the one used in
             this protocol.

          7. Any medical disability, condition or laboratory abnormality (e.g., severe degenerative
             arthritis, compromised nutritional state, body weight less than 15% of ideal, Na less
             than 130 (grade 3 or above), cardiovascular disease) that would be deemed likely to
             increase risk of participation in the protocol or interfere with assessment of the
             safety and biologic effect of study materials, the chronic implantation of catheters
             and infusion pumps, or would compromise the ability of the subject to give informed
             consent.

          8. Known allergy to E coli-derived products or history of anaphylaxis.

          9. Treatment with an investigational agent or used an investigational device within 60
             days before the first dose of study material, other than those described in this
             protocol.
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00005903

Organization ID

000145

Secondary IDs

00-N-0145


Study Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)


Study Sponsor

, , 


Verification Date

May 2005